PRCT

PROCEPT BioRobotics Corporation

Healthcare · $1.0B market cap

We can't put a fair value on PRCT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?

Equity per share growth21.7% a year✓

Sales growth72.9% a year✓

Free cash flow growth—?

Return on invested capital-24.6%✗

Follow PRCT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 9, 2026: no open-market purchases and 3 sales worth $22K. Why purchases matter

Sales

Waters Kevin

EVP, CFO · 2026-09-09

Sold

$8K

Templin Barry L

EVP, Chief Technology Officer · 2026-09-09

Sold

$8K

Nouri Alaleh

EVP, CLO, CORP. SEC. · 2026-09-09

Sold

$6K

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works

Verdict

Business quality

Insider activity

Sales

About PROCEPT BioRobotics Corporation